NSE filing, NSE: SUNPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,770.00
- Market cap
- ₹4,24,682 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 38.7×Sector 47.2×
- Promoter holding
- 52.68%-1.80% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Annual General Meeting
Sun Pharma's postal ballot passed all seven special resolutions, including ESOP 2026 approval and borrowing and security limits. No monetary transaction is stated.
Sun Pharmaceutical Industries Earnings Call Transcript: Key Takeaways
Sun Pharma delivered resilient double-digit revenue growth despite U.S. specialty headwinds, masking underlying margin pressure from lower Lenalidomide sales.
Sun Pharmaceutical Industries Other Announcement
Sun Pharma's board appointed Deloitte as Statutory Auditors under mandatory rotation, effective from the FY 2026-27 AGM. This follows SRBC & CO's second five-year term completion.
Sun Pharmaceutical Industries Q2 FY27 Results: Net Profit ₹1,995 Cr, Down 36.2% YoY
Sun Pharmaceutical Industries Ltd reported revenue from operations of ₹16,199 Cr (+11.9% YoY) and net profit of ₹1,995 Cr (-36.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,995 Cr · -36.2% YoY
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
Sun Pharmaceutical Industries Debt & Borrowing: ₹7,816 Cr
Sun Pharma completed allotment of ₹7,816 crore NCDs via private placement, exercising its greenshoe option of ₹816 crore. The unsecured debentures carry 8.05–8.20% coupons maturing October 2031.
- Value
- ₹7,816 Cr
- Execution
- 5 years and 1 day (26 Oct 2026 to 27 Oct 2031)
Other price movement clarification announcements
All →Tata Communications Price Movement Clarification
Tata Communications responded to a news report on STT GDC India's sale, stating no material event requires Regulation 30 disclosure. It will disclose as required.
Milton Industries Price Movement Clarification
Milton Industries responded to NSE's 29 October 2026 query on significant share price movement. The company said no undisclosed price-sensitive information exists and the move is market-driven.
Mazagon Dock Shipbuilders Price Movement Clarification
Mazagon Dock clarified a news report on proposed shipbuilding hubs amid a share price move. The company is exploring partnerships and financing, with no value disclosed.
Dhvija Finance Price Movement Clarification
Dhvija Finance Ltd stated the price movement is market-driven with no undisclosed events, confirming full regulatory compliance. No impending announcements exist beyond upcoming Q3 results.
Solex Energy Price Movement Clarification
Solex Energy clarified to the exchange that no specific US market negotiations exist. The company confirmed no unpublished material information requiring disclosure.
Gulf Oil Lubricants India Price Movement Clarification
Gulf Oil Lubricants clarified a news item about Gulf Oil International's global expansion plans, stating no negotiations were entered into. The price movement is described as market-driven with no undisclosed event.